No matches
Type 2 Inflammation

Unraveling the Link of Type 2 Inflammation and Airway Remodeling in Asthma

Join Dr. Celeste Porsbjerg as she discussed on how type 2 inflammation may lead to airway remodeling in asthma, exploring the pathophysiologic mechanisms, that ultimately lead to structural changes and irreversible loss of lung function
Celeste Porsbjerg
MD, PhD
Celeste Porsbjerg

Learning objectives

  • Understand the role of type 2 inflammation in airway remodeling
  • Recognize the role of IL-13 and IL-4 in the pathophysiological mechanisms underlying airway remodeling

Description

In this videoclip, from the ERS 2024 symposium, Dr. Celeste Porsbjerg discusses how T2 inflammation may cause changes in the airway epithelium, leading to increased mucus plugging

Tags
airway remodelingasthmaIL-13IL-4
MAT-GLB-2503457 - 1.0 - 07/2025

About this expert

Pulmonology

Celeste Porsbjerg

MD, PhD

Professor of Severe Asthma, Bispebjerg Hospital Copenhagen, Denmark

See author’s profile
Celeste Porsbjerg

Related resources

ERS 2023 | Adult Asthma Symposium: Mini Debate
Pulmonology
expert video

ERS 2023 | Adult Asthma Symposium: Mini Debate

ERS 2023 | Adult Asthma Symposium: Panel Discussion
Pulmonology
expert video

ERS 2023 | Adult Asthma Symposium: Panel Discussion

ERS 2023 | Advancing Asthma Management Beyond Control
Pulmonology
expert video

ERS 2023 | Advancing Asthma Management Beyond Control

ERS 2023 | Assessing Disease Activity to Better Define On-Treatment Clinical Remission in Pediatric Severe Asthma
Pulmonology
expert video

ERS 2023 | Assessing Disease Activity to Better Define On-Treatment Clinical Remission in Pediatric Severe Asthma

ERS 2023 | Burden of Underlying Disease in Pediatric Severe Asthma
Pulmonology
expert video

ERS 2023 | Burden of Underlying Disease in Pediatric Severe Asthma

ERS 2023 | Evolving Patient Care: From Symptom Control to On-Treatment ​Clinical Remission​
Pulmonology
expert video

ERS 2023 | Evolving Patient Care: From Symptom Control to On-Treatment ​Clinical Remission​

ERS 2023 | How Achievable Is Clinical Remission on Biologic Therapy?
Pulmonology
expert video

ERS 2023 | How Achievable Is Clinical Remission on Biologic Therapy?

ERS 2023 | On-Therapy Remission in Pediatric Asthma: Where Are We Today?
Pulmonology
expert video

ERS 2023 | On-Therapy Remission in Pediatric Asthma: Where Are We Today?

ERS 2023 | Pediatric Asthma Symposium: Patient Case Discussion
Pulmonology
expert video

ERS 2023 | Pediatric Asthma Symposium: Patient Case Discussion

ERS 2023 | Progression of Underlying Disease in Pediatric Severe Asthma
Pulmonology
expert video

ERS 2023 | Progression of Underlying Disease in Pediatric Severe Asthma

ERS 2023 | Type 2 Biomarkers as Predictive and Prognostic Tools to Guide Management
Pulmonology
expert video

ERS 2023 | Type 2 Biomarkers as Predictive and Prognostic Tools to Guide Management

Type 2 Inflammation Underpins Pediatric Severe Asthma
Pulmonology
Infographic

Type 2 Inflammation Underpins Pediatric Severe Asthma

GINA-Based Opportunities for Improved Outcomes With Effective Management of Pediatric Asthma in Children 6-11 Years of Age
Pulmonology
interactivity

GINA-Based Opportunities for Improved Outcomes With Effective Management of Pediatric Asthma in Children 6-11 Years of Age

Role of Type 2 Inflammation in Skin Barrier Dysfunction in AD
Type 2 Inflammation
expert video

Role of Type 2 Inflammation in Skin Barrier Dysfunction in AD

Importance of Lung Function Assessment in Pediatric Asthma Patients
Pulmonology
videoanimation

Importance of Lung Function Assessment in Pediatric Asthma Patients

ADVENT On Air | What Is the Future Outlook for Remission in Pediatric Severe Asthma?
Pulmonology
Podcast

ADVENT On Air | What Is the Future Outlook for Remission in Pediatric Severe Asthma?

EAACI 2024 Moving Beyond Control To On-Treatment Clinical Remission
Pulmonology
expert video

EAACI 2024 Moving Beyond Control To On-Treatment Clinical Remission

EAACI 2024 Evolving Perspectives in CRSwNP Patient Care
Pulmonology
expert video

EAACI 2024 Evolving Perspectives in CRSwNP Patient Care

ADVENT On Air | The Road Ahead: Achieving Remission for ​Patients With Asthma
Pulmonology
Podcast

ADVENT On Air | The Road Ahead: Achieving Remission for ​Patients With Asthma

Eosinophils as a Biomarker for Type 2 Asthma
Pulmonology
expert video

Eosinophils as a Biomarker for Type 2 Asthma

Airway Remodeling in Type 2 Asthma is Driven by IL-4 and IL-13
Pulmonology
expert video

Airway Remodeling in Type 2 Asthma is Driven by IL-4 and IL-13

ERS 2024 | Understanding the Complex Pathophysiology of COPD
Pulmonology
expert video

ERS 2024 | Understanding the Complex Pathophysiology of COPD

COPD and Asthma: What's the Difference and Is There a Link?
Pulmonology
interactivity

COPD and Asthma: What's the Difference and Is There a Link?

What Are the Key Inflammatory Processes in Patients with COPD?
Pulmonology
expert video

What Are the Key Inflammatory Processes in Patients with COPD?

Burdens Experienced by Pediatric Asthma Patients and Their Caregivers
Pulmonology
expert video

Burdens Experienced by Pediatric Asthma Patients and Their Caregivers

Clinical Remission as a Goal in Asthma Clinical Practice
Pulmonology
expert video

Clinical Remission as a Goal in Asthma Clinical Practice

Concerns Surrounding OCS Side Effects in Patients With Severe Asthma
Pulmonology
expert video

Concerns Surrounding OCS Side Effects in Patients With Severe Asthma

Expert Insights: Importance of Lung Function Assessment in Pediatric Asthma Patients
Pulmonology
expert video

Expert Insights: Importance of Lung Function Assessment in Pediatric Asthma Patients

FeNO as a Biomarker for Type 2 Asthma
Pulmonology
expert video

FeNO as a Biomarker for Type 2 Asthma

How Can FeNO Support the Management of Pediatric Asthma?
Pulmonology
expert video

How Can FeNO Support the Management of Pediatric Asthma?

IgE as a Biomarker for Type 2 Asthma
Pulmonology
expert video

IgE as a Biomarker for Type 2 Asthma

Importance of Lung Function Assessment in Adult Asthma Patients
Pulmonology
videoanimation

Importance of Lung Function Assessment in Adult Asthma Patients

Monitoring Lung Function Is an Important Aspect of Pediatric Asthma Management
Pulmonology
interactivity

Monitoring Lung Function Is an Important Aspect of Pediatric Asthma Management

Mucus Plugging Is a Key Component of Remodeling in Asthma, Leading to Fixed Airway Obstruction
Pulmonology
Infographic

Mucus Plugging Is a Key Component of Remodeling in Asthma, Leading to Fixed Airway Obstruction

Pediatric Asthma Patient Case Tool: Ash
Pulmonology
interactivity

Pediatric Asthma Patient Case Tool: Ash

The Cycle of Inflammation in Adult Asthma
Pulmonology
interactivity

The Cycle of Inflammation in Adult Asthma

Type 2 Inflammation Is a Significant Driver of Pediatric Severe Asthma
Pulmonology
Infographic

Type 2 Inflammation Is a Significant Driver of Pediatric Severe Asthma

Type 2 Inflammation Mediates Severe Asthma in Pediatric Patients
Pulmonology
expert video

Type 2 Inflammation Mediates Severe Asthma in Pediatric Patients

What is the Role of FeNO as an Asthma Biomarker?
Pulmonology
expert video

What is the Role of FeNO as an Asthma Biomarker?

ERS 2024 | Panel Discussion: What Might Be Required for On-Therapy Remission in Pediatric Severe Asthma?
Pulmonology
expert video

ERS 2024 | Panel Discussion: What Might Be Required for On-Therapy Remission in Pediatric Severe Asthma?

ADVENT On Air | Breathing Easy: Navigating Lung Function in Pediatric Severe Asthma With Spirometry and Beyond
Pulmonology
Podcast

ADVENT On Air | Breathing Easy: Navigating Lung Function in Pediatric Severe Asthma With Spirometry and Beyond

FeNO: A Biomarker of Type 2 Inflammation in Pediatric Asthma Patients
Pulmonology
Infographic

FeNO: A Biomarker of Type 2 Inflammation in Pediatric Asthma Patients

Blood Eosinophils: A Biomarker in COPD
Pulmonology
Infographic

Blood Eosinophils: A Biomarker in COPD

GOLD 2023 | Clinical Presentation of COPD and Disease Burden
Pulmonology
expert video

GOLD 2023 | Clinical Presentation of COPD and Disease Burden

What Do We Know About Type 2 Inflammation in COPD?
Pulmonology
expert video

What Do We Know About Type 2 Inflammation in COPD?

What Differentiates COPD Exacerbations From Asthma Exacerbations?
Pulmonology
expert video

What Differentiates COPD Exacerbations From Asthma Exacerbations?

The Heterogeneity of Underlying Inflammation in Patients With COPD
Pulmonology
expert video

The Heterogeneity of Underlying Inflammation in Patients With COPD

ERS 2024 | What Do We Know About IL-33 Genetics?
Pulmonology
expert video

ERS 2024 | What Do We Know About IL-33 Genetics?

Pathways to Disease: Inflammation in Chronic Obstructive Pulmonary Disease Video
Pulmonology
videoanimation

Pathways to Disease: Inflammation in Chronic Obstructive Pulmonary Disease Video

ATS 2024 | Type 2 Inflammation in the Pathophysiology of Asthma and COPD: What Is It and How Does It Impact Patients?
Pulmonology
expert video

ATS 2024 | Type 2 Inflammation in the Pathophysiology of Asthma and COPD: What Is It and How Does It Impact Patients?

ADVENT is a global medical education non-promotional program by Sanofi and Regeneron. This website is intended only for duly authenticated healthcare professionals in Algeria, Argentina, Australia, Austria, Bahrain, Belgium, Brazil, Bulgaria, Canada, Chile, China, Colombia, Costa Rica, Croatia, Czech Republic, Denmark, Dominican Republic, Ecuador, Egypt, Estonia, Finland, France, Germany, Greece, Guatemala, Hong Kong, Hungary, Iceland, India, Israel, Italy, Japan, Kuwait, Latvia, Lebanon, Lithuania, Macau, Malaysia, Norway, Oman, Panama, Peru, Poland, Portugal, Qatar, Romania, Saudi Arabia, Singapore, Slovenia, South Africa, South Korea, Spain, Sudan, Sweden, Switzerland, Taiwan, Thailand, The Netherlands, Turkey, United Arab Emirates, or the United States of America.

For healthcare professionals in Algeria: Please read the additional Terms of Use.

Sanofi | Regeneron Logo

© 2025 Sanofi and Regeneron Pharmaceuticals, Inc.

All rights reserved.
MAT-GLB-2302957 v3.0 11/2023

All Rights Reserved.

Sanofi and Regeneron are global leaders in pharmaceutical development, each with a long history of supporting frontline physicians to improve human health and reduce the burden of disease. Driven by the same commitment to patients and their families, Sanofi and Regeneron have partnered to take on type 2 inflammation and the range of chronic conditions in which excessive inflammation plays a role.

Country/region: PortugalChange country/region